Skip to main content
Caplight Logo









Melius Pharma

Melius Pharma

Private
StockholmHealthcare & Life Scienceshttps://www.meliuspharma.com/

Last Round

Series A

May 3, 2022

Est. Valuation

$4.66M

Total Funding Raised

$1.82M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Melius Pharma is a Swedish clinical-stage pharmaceutical company developing a therapy for Th2-associated refractory chronic cough (RCC).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

chronic cough treatmentIdiopathic Pulmonary FibrosisIPFSuplatast Tosilaterefractory chronic coughRCCrespiratory disease therapyde-risked drug developmentPhase 2 clinical trialdrug in-licensingimmunomodulatory therapyvirtual biotechpharma partneringrare lung diseaseTh2 inflammation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Melius Pharma Comparables

Compare Melius Pharma with similar companies based on industry and business-model similarity.

Melius Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Seyltx, Inc.
83%
Algernon Health Inc.
80%
NeRRe Therapeutics
79%

Melius Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 3, 2022

Key People

Founding team and executive leadership

Mark Kornfeld

CEO

Executive Team

Melius Pharma Investors

Notable investors and investment history

Melius Pharma investors
InvestorRounds
Fåhraeus Startup and GrowthSeries A
Linc ABSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 35% MoM.

  • Jan 19, 2026

    Monthly visitors increased 58% MoM.

Melius Pharma Filings

Explore SEC and related filing metadata, where available.

Melius Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Melius Pharma's valuation, stock price, and market status.

Is Melius Pharma a public or private company?

Melius Pharma is a private company.

What is the current stock price of Melius Pharma?

Melius Pharma is a private company with no public stock price. No recent secondary market data is available.

How much is Melius Pharma worth (valuation)?

Melius Pharma's valuation is estimated at $4.7M based on funding round data.

Can I buy Melius Pharma stock?

Melius Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Melius Pharma's last funding round?

Melius Pharma's most recent funding round was Series A on May 3, 2022.

Who are the main investors in Melius Pharma?

Key investors in Melius Pharma include Fåhraeus Startup and Growth, Linc AB.

Will Melius Pharma IPO soon?

No public IPO plans have been announced for Melius Pharma.

How can I track Melius Pharma secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Melius Pharma's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStockholm
Employee Range2
Year Founded2021
Last FundingMay 3, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?